BridgeBio Raises $934M in 7% Preferred Eight Weeks After Buyback Authorization
Capital Strategy Shift
Company Background
BridgeBio Pharma is a Palo Alto-based commercial-stage biopharmaceutical company focused on genetic diseases. Its first approved product, Attruby (acoramidis), a transthyretin stabilizer for ATTR-CM, launched in the United States in November 2024 and generated $180.6 million in net product revenue in the first quarter of 2026 alone. Total revenues for full-year 2025 came to $502.1 million, nearly all of it from Attruby's rapid ramp.
Three additional drugs — BBP-418 for a rare muscular dystrophy (LGMD2I/R9), encaleret for a genetic calcium disorder (ADH1), and infigratinib for achondroplasia — each completed positive Phase 3 trials between October 2025 and February 2026, with NDAs submitted or planned for all three. The company is building commercial teams for each launch simultaneously. Cash stood at $940.2 million as of March 31, 2026, but operating cash burn was approximately $197 million in that quarter, and the balance sheet carries more than $2.4 billion in convertible notes across four tranches maturing between 2027 and 2033, alongside $871 million in deferred royalty obligations.
What Was Disclosed
BridgeBio sold 933,900 shares of newly created Series A Cumulative Convertible Participating Preferred Stock at $1,000 per share, raising $933.9 million in aggregate. Sixth Street, acting through Chinotto Investments LLC, provided $800 million, while HealthCare Royalty — a business majority-owned by KKR — provided the remaining $133.9 million through HCRx Investments HoldCo LP. The Investment Agreement also gives Sixth Street an option to invest up to an additional $66.1 million on the same terms, subject to board approval.
The preferred carries a 7% annual cumulative dividend that accrues daily whether or not declared, payable quarterly either in cash or by compounding into the liquidation value at BridgeBio's election. The rate is not fixed: it jumps 500 basis points on the seventh anniversary of the deal (to 12%), then rises a further 125 basis points every three months thereafter up to a cap of 17%, and increases by another 300 basis points during any defined triggering event. Holders convert into common stock at an initial price of $137.79 per share, rising to $153.10 from the fifth anniversary onward; BridgeBio framed both as more than 100% and 125% premiums, respectively, to the company's 30-day volume-weighted average price at signing. The company may force conversion after three years if the stock trades above 200% of the conversion price for 20 of 30 consecutive trading days.
From the moment the preferred was issued, common stockholders became subordinated to the preferred in dividend rights and in any liquidation or winding-up. The Certificate of Designations also placed explicit restrictions on BridgeBio's ability to repurchase or redeem common shares so long as any preferred remains outstanding, and the Investment Agreement imposes additional consent rights over certain new debt and restricted payments. A majority of preferred holders must approve any amendment to the company's charter that adversely affects the preferred, as well as any issuance of parity or senior equity. BridgeBio has agreed to seek shareholder approval at its 2027 annual meeting — or at a special meeting no later than June 30, 2027 — to permit full conversion without the current 19.9% per-holder beneficial ownership cap that Nasdaq rules otherwise impose.
Why It Matters
The timing creates a direct tension with an earlier capital commitment. On May 6, the board authorized a $500 million common stock repurchase program, and CEO Neil Kumar publicly described buybacks as offering "an attractive risk-adjusted return relative to other uses of capital" because the company was "fully financed but trading at a deep discount to intrinsic value." Eight weeks later, those same buybacks became subject to preferred-holder consent under the terms of this deal. The company has not explained publicly what changed between May 6 and July 1 in its assessment of either the intrinsic value discount or its financing needs. The January 2026 issuance of $632.5 million in convertible notes at 0.75% interest — raised at the time as a straightforward debt-management transaction — means BridgeBio has now layered a 7%-to-17% preferred instrument on top of a balance sheet that was already net-deficit by more than $2.2 billion at March 31, 2026.
There is a disclosed conflict embedded in the deal structure. Ali Satvat, a member of BridgeBio's board, is a partner at Kohlberg Kravis Roberts, the firm that controls HealthCare Royalty. HCRx and BridgeBio also had a prior commercial relationship: HCRx participated in a June 2025 royalty financing that provided $300 million in proceeds. The filing identifies the HCRx purchaser as a holder of more than 5% of BridgeBio's common stock, making the transaction a related-party deal under that threshold.
The bullish read on this transaction is not without substance. BridgeBio is attempting to simultaneously launch four commercial products — a capital undertaking with few precedents in rare-disease biopharma — and the preferred carries no scheduled maturity and cannot be put back to the company by holders. The conversion premium structure means dilution is modest at current prices, and the company's revenue trajectory (Attruby net product revenue grew from $71.5 million in Q2 2025 to $180.6 million in Q1 2026) gives it plausible runway toward self-funding the launches. But the escalating dividend clock — particularly the step to 12% at year seven and the 13% IRR floor that governs change-of-control redemptions — means the cost of leaving the preferred outstanding for an extended period could become substantial.